Vancomycin and gentamicin in neonates: Hindsight, current controversies, and forethought

Journal of Perinatal and Neonatal Nursing

Volumn 16, Issue 2, 2002, Pages 54-72

  Dawson, Patricia Marie ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Antibiotic; Gentamicin; Infection; Neonatal intensive care unit; Neonate; Resistance; Sepsis; Vancomycin

Indexed keywords

ANTIINFECTIVE AGENT; GENTAMICIN; VANCOMYCIN;

BACTEREMIA; BACTERIAL INFECTION; HUMAN; NEWBORN; NEWBORN INTENSIVE CARE; NEWBORN SCREENING; REVIEW; UNITED STATES;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BACTERIAL INFECTIONS; GENTAMICINS; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; NEONATAL SCREENING; UNITED STATES; VANCOMYCIN;

EID: 0036715617     PISSN: 08932190     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005237-200209000-00006     Document Type: Article

References (39)

1. Danish M. Clinical pharmacokinetics. In: Yaffe S, Aranda J, eds. Pediatric Pharmacology: Therapeutic Principles in Practice. Philadelphia: W.B. Saunders; 1992:22-28.
2. Noerr B. Pointers in practical pharmacology: gentamicin. Neonatal Network. 1995; 8:75-77.
3. Baltimore RS. Neonatal nosocomial infections. Semin Perinatol. 1998;1:25-32.
4. Blackburn ST, Loper DL. Maternal, Fetal, and Neonatal Physiology: A Clinical Perspective. Philadelphia: W.B. Saunders; 1992.
5. Henry NK, Hoecker JL, Rhodes KH. Antimicrobial therapy for infants and children: guidelines for the inpatient and outpatient practice of pediatric infectious diseases. Mayo Clin Proc. 2000;1:86-97.
6. de Alba Romero C, Castillo EG, Secades CM, Lopez JR, Lopez LA, Valiente PS. Once daily gentamicin dosing in neonates. Pediatr Infect Dis J. 1998;12:1169-1171.
7. Jarvis WR. The epidemiology of colonization. Infect Control Hosp Epidemiol. 1996;1:47-52.
8. Baier RJ, Bocchini JA, Brown EG. Selective use of vancomycin to prevent coagulase-negative staphylococcal nosocomial bacteremia in high-risk very low birth weight infants. Pediatr Infect Dis J. 1998;17:179-183.
9. Sater KJ. Treatment of sepsis in the neonate. J IV Nurs, 1998;5:275-281.
10. Vermont CL, Hartwig NG, Fleer A, et al. Persistence of clones of coagulase-negative staphylococci among premature neonates in neonatal intensive care units: two-center study of bacterial genotyping and patient risk factors. J Clin Microbiol. 1998;9:2485-2490.
11. Isaacs D. Rationing antibiotic use in neonatal units. Arch Dis Child. 2000;82:F1-F2.
12. Freeman J, Epstein MF, Smith NE, Platt R, Sidebottom DG, Goldmann DA. Extra hospital stay and antibiotic usage with nosocomial coagulase-negative bacteremia in two neonatal intensive care unit populations. Am J Dis Child. 1990;144:324-329.
13. Rojas MA, Gonzalez A, Bancalari E, Claure N, Poole C, Silva-Neto G. Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease. J Pediatr. 1995;126:605-610.
14. Pawlotsky F, Thomas A, Kergueris MF, Debillon T, Roze JC. Constant rate infusion of vancomycin in premature neonates: a new dosage schedule. Br J Clin Pharmacol. 1998;46:163-167.
15. Remington JS, Klein JO. Infectious Diseases of the Fetus and Newborn Infant. 4th ed. Philadelphia: W.B. Saunders; 1995.
16. Müller D, Hufnagel M, Suttorp M. Accidental overdose of vancomycin in preterm twins. Pediatr Infect Dis J. 1999;8:744-745.
17. de Hoog M, Schoemaker RC, Mouton JW, van den Anker JN. Vancomycin population pharmacokinetics in neonates. Clin Pharmacol Ther. 2000;4:360-367.
18. Amaker RD, Bhatia J. ECMO and pharmacotherapy. Neonatal Network. 1996;8:58.
19. Cooke RWI, Nycyk JA, Okunghuae H, Shah V, Damjanovic V, Hart CA. Low-dose vancomycin prophylaxis reduces coagulase-negative staphylococcal bacteraemia in very low birthweight infants. J Hosp Infect. 1997;37:297-303.
20. Fallat ME, Gallinaro RN, Stover BH, Wilkerson S, Goldsmith LJ. Central venous catheter bloodstream infections in the neonatal intensive care unit. J Pediatr Surg. 1998;9:1383-1387.
21. Ocete E, Ruiz-Extremera A, Goicoechea A, et al. Low-dosage prophylactic vancomycin in central venous catheters for neonates. Early Hum Dev. 1998;53:S181-S186.
22. Cohen FL, Tartasky D. Microbial resistance to drug therapy: a review. Am J Infect Control. 1997;1:51-64.
23. Christenson JC, Korgenski EK, Jenkins E, Daly JA. Detection of vancomycin-resistant enterococci colonization in a children's hospital. Am J Infect Control. 1998;6:569-571.
24. Malik RJ, Montecalvo MA, Reale MR, et al. Epidemiology and control of vancomycin-resistant enterococci in a regional neonatal intensive care unit. Pediatr Infect Dis J. 1999;18:352-356.
25. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance: recommendations of the Hospital Infection Control Practices Advisory Committee. MMWR. 1995;44:1-13.
26. Roe VA. Antimicrobial agents: pharmacology and clinical application in obstetric, gynecologic, and perinatal infections. J Obstet Gynecol Neonatal Nurs. 1999;6:639-648.
27. Roghmann MC, Perdue BE, Polish L. Vancomycin use in a hospital with vancomycin restriction. Infect Control Hasp Epidemiol. 1999;1:60-63.
28. van Houten MA, Uiterwaal CSPM, Heesen GJM, Arends JP, Kimpen JLL. Does the empiric use of vancomycin in pediatrics increase the risk of gram-negative bacteremia? Pediatr Infect Dis J. 2001; 2:171-177.
29. Davies MW, Cartwright DW. Gentamicin dosing intervals in neonates: longer dosage interval - less toxicity. J Paediatr Child Health. 1998;34:577-580.
30. Thureen PJ, Reiter PD, Gresores A, Stolpman NM, Kawato K, Hall DM. Once-versus twice-daily gentamicin dosing in neonates ≥34 weeks' gestation: cost-effectiveness analyses. Pediatrics. 1999;3: 594-598.
31. Corder L, Sananes M, Ayers LW. Failure of systemic antibiotics to eradicate gram-negative bacilli from the airway of mechanically-ventilated very-low-weight infants. Am J Infect Control. 2000;4:286-291.
32. Skopnick H, Wallraf R, Nies B, Tröster K, Heimann G. Pharmacokinetics and antibacterial activity of daily gentamicin. Arch Dis Child. 1992;67:57-61.
33. Noerr B. Pointers in practical pharmacology: gentamicin dosing recommendations. Neonatal Network. 2000;4:81-86.
34. Lopez-Samblas AM, Torres CL, Wang H, Feuer WJ, Goldberg RN. Effectiveness of a gentamicin dosing protocol based on post-conceptional age: comparison to published neonatal guidelines. Ann Pharmacother. 1992;26:534-538.
35. Logsdon BA. Gentamicin 3 mg/kg dosing and monitoring within the first 7 days of life. J Pediatr Pharm Pract. 1999;2:77-79.
36. Langlass TM, Mickle TR. Standard gentamicin dosage regimen in neonates. Am J Health Syst Pharmacol. 1999;56:440-442.
37. Vervelde ML, Rademaker CMA, Krediet TG, Fleer A, van Asten P, van Dijk A. Population pharmacokinetics of gentamicin in preterm neonates: evaluation of a once-daily dosage regimen. Ther Drug Monit. 1999;21:514-519.
38. Yeung MY, Downe LM, Coughtrey HE. Gentamicin doses and dose intervals in neonatal intensive care. J Paediatr Child Health. 1999;35:411-413.
39. Lundergan FS, Glasscock GF, Kim EH, Cohen RS. Once-daily gentamicin dosing in newborn infants. Pediatrics. 1999;6:1228-1234.